First Patient Enrolled in REPRISE II TAVR Clinical Trial to Evaluate the Safety and Performance of the Lotus™ Valve System (via PR Newswire)
NATICK, Mass., Oct. 10, 2012 /PRNewswire/ — Boston Scientific (NYSE: BSX) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™ Valve System in up to 120 patients with severe aortic valve disease. This international, multi-center…
published: October 15, 2012 in: Boston Scientific, Cardio, Clinical Studies/Trials